The clinical model is capital-intensive and heavily regulated, with Medicare reimbursement rates set annually by the federal government — a structural constraint that makes every basis point of operational efficiency meaningful. Dialysis patients do not choose to reduce their treatment frequency because of high prices or economic downturns. That inelasticity produces stability, but the Medicare and Medicaid reimbursement system that governs roughly 90% of DaVita's U.S. Patient base also caps the upside. The economics of that model are still being demonstrated. By 1998, Total Renal Care Holdings was in serious trouble. Revenue was large but the financial structure was fragile. The board needed someone who could stabilize the company rather than simply manage it. The 2005 acquisition of Gambro Healthcare's U.S. Dialysis business was transformational.
The stakes are high: DaVita must prove it can maintain pricing power in an environment where Medicare rate increases lag inflation, commercial insurers are aggressively managing costs, and the federal government is promoting home dialysis and transplants as alternatives to in-center hemodialysis. The problem is, the Medicare fee-for-service market is regulated, with rates set by CMS, so competition centers on quality metrics, patient satisfaction, and cost efficiency rather than pricing. While within covenant limits, the debt load creates vulnerability to any sustained downturn in volumes, pricing, or margins. Here's why: Success in IKC requires care coordination capabilities, data analytics, and risk management infrastructure that differ from traditional fee-for-service dialysis operations.